Cutia Therapeutics’ CU-20401 Completes Phase I Study for Obesity Treatment
China-based dermatology specialist Cutia Therapeutics (HKG: 2487) has announced the last subject out (LSO) in...
Peking University Unveils National Standardized Pain Treatment Center in China
Peking University People’s Hospital has officially unveiled the plaque for the National Standardized Pain Treatment...
Leadinno Medical Valley Secures Series A+ Funding for Neuroregulation Device R&D
Leadinno Medical Valley, a Beijing-based innovator in pain management and neuroregulation devices, has reportedly secured...
China Grand Pharma Initiates Phase III Trial for GPN00833 in Cataract Surgery Recovery
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced a significant milestone...
Gates Foundation Funds CanSino’s Innovative Polio Vaccine Development
The Bill & Melinda Gates Foundation has announced a commitment of USD 2 million to...
OrbiMed Raises Over USD 4.3 Billion for Private Investment Funds Focused on Healthcare
US-based investment fund giant OrbiMed has announced the successful raising of over USD 4.3 billion...
BMS Regains Full Rights to Mavacamten in China and Asia from LianBio
Bristol-Myers Squibb (BMS; NYSE: BMY) is set to regain full control of mavacamten, a treatment...
Sihuan Pharmaceutical Gains NMPA Approval for Innovative Type 2 Diabetes Treatment
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical...
Jiangsu Aidea’s HIV-1 Drug ACC017 Accepted for NMPA Review in China
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...
Shandong Luoxin’s LX-039 Demonstrates Promise in Phase I Oncology Study at ESMO
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a China-based pharmaceutical innovator, has published...
Kintor’s Proxalutamide Shows Promise in Metastatic Breast Cancer Study at ESMO
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has published the latest data from a Phase Ic...
Walvax Biotechnology Secures BPOM Approval for Weuphoria Pneumococcal Vaccine
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received market approval...
NMPA Implements New Measures for Drug Manufacturing Outsourcing by MAHs
The National Medical Products Administration (NMPA) has issued a notice detailing new supervision and management...
Ascentage Pharma’s Pelcitoclax Shows Promise in ESMO Study for NSCLC
Suzhou-based pharmaceutical company Ascentage Pharma (HKG: 6855) has published the latest results from a Phase...
Changchun BCHT Biotechnology Invests in Influenza Vaccine Production Expansion
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced plans to invest RMB 805...
Yiling Pharmaceutical Gains NMPA Approval for XY0206 in AML Trial
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...
Chengdu Kanghong Receives FDA Nod for Clinical Trial of Novel Depression Therapy KH607
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced that it has received...
Blue Sail Medical Enrolls First Patient in Study for Rapamycin-Coated Balloon Catheter
China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced a significant milestone with the...
Transcenta Holdings Unveils Updated Osemitamab Data in Advanced Gastric Cancer at ESMO
China-based biotech Transcenta Holdings Ltd (HKG: 6628) has presented updated efficacy data from the expansion...
Vcanbio Receives NMPA Approval for Clinical Study of VUM02 in SR-aGvHD Treatment
China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that...